BCTX Stock Chart & Stats
$4.03
-$0.14(-3.76%)
At close: 4:00 PM EDT
$4.03
-$0.14(-3.76%)
Day’s Range― - ―
52-Week Range$2.60 - $14.68
Previous Close$0.41
Volume63.94K
Average Volume (3M)441.66K
Market Cap
$31.08M
Enterprise Value-$1.60M
Total Cash (Recent Filing)$22.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding8,699,787
10 Day Avg. Volume1,092,057
30 Day Avg. Volume441,657
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit60.36
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-free balance sheet limits interest obligations and lender constraints, giving BriaCell greater flexibility to fund research and clinical development. This reduces solvency risk relative to similarly loss-making biotechnology companies, although it does not remove financing needs.
Focused Oncology PipelineA focused pipeline centered on Bria-IMT and combination approaches can concentrate capital, clinical expertise, and regulatory efforts around a defined oncology opportunity. Successful development could create meaningful product optionality, though approval and commercialization remain uncertain.
Improving Equity BaseThe increase in reported equity provides a stronger capital base than the prior year and helps absorb ongoing development costs. It may support near-term operating continuity, though the improvement must be viewed alongside continuing losses and the company’s likely need for additional capital.
Bears Say
Pre-Revenue Business ModelWith no reported revenue, BriaCell lacks commercial cash inflows to fund research, trials, and corporate expenses. Its financial outlook therefore depends heavily on clinical progress, partnerships, or external financing until a candidate reaches approval and commercialization.
Persistent Operating LossesLarge recurring losses indicate that development spending has not yet produced operating leverage or revenue replacement. Continued losses can erode capital and limit strategic flexibility, making future results highly dependent on clinical milestones and disciplined expense management.
High Cash Burn And Financing DependenceSustained cash outflows directly consume resources needed for trials and operations, while the worsening burn versus 2025 increases the probability of future fundraising. Additional financing could dilute existing holders or be unavailable on favorable terms if development risk rises.
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $2.60 and its highest was $14.68 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is $31.08M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 44 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Jun 09, 2026. The company reported -$0.962 earnings per share for the quarter.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 8,699,787 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$0.962 in its last earnings report. Following the earnings report the stock price went down -6.189%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Ownership Overview
32.39% Insiders
4.63% Other Institutional Investors
62.99% Public Companies and
Individual Investors